Evidence map›Paper›PMID 34282988›Full record

ArticleInternational journal of stroke : official journal of the International Stroke Society2022

Prehemorrhage antiplatelet use in aneurysmal subarachnoid hemorrhage and impact on clinical outcome.

Martina Sebök, Isabel C Hostettler, Emanuela Keller, Ilari M Rautalin, Bert A Coert, William P Vandertop, René Post, Ali Sardeha, Maud A Tjerkstra, Luca Regli and 2 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of stroke : official journal of the International Stroke Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Microthrombi and hypercoagulability's contribution to delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2026
    Review
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Martina SebökDepartment of Neurosurgery, University Hospital Zurich, Zurich, Switzerland.ORCID 0000-0002-7246-3421
Isabel C HostettlerStroke Research Centre, University College London, Institute of Neurology, London, UK.
Emanuela KellerClinical Neuroscience Center, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Ilari M RautalinDepartment of Neurosurgery, Helsinki University Hospital, Helsinki, Finland.
Bert A CoertDepartment of Neurosurgery, Amsterdam University Medical Center, Amsterdam, the Netherlands.
William P VandertopDepartment of Neurosurgery, Amsterdam University Medical Center, Amsterdam, the Netherlands.ORCID 0000-0001-5417-0265
René PostDepartment of Neurosurgery, Amsterdam University Medical Center, Amsterdam, the Netherlands.
Ali SardehaDepartment of Neurosurgery, Amsterdam University Medical Center, Amsterdam, the Netherlands.
Maud A TjerkstraDepartment of Neurosurgery, Amsterdam University Medical Center, Amsterdam, the Netherlands.
Luca RegliDepartment of Neurosurgery, University Hospital Zurich, Zurich, Switzerland.
Dagmar VerbaanDepartment of Neurosurgery, Amsterdam University Medical Center, Amsterdam, the Netherlands.
Menno R GermansDepartment of Neurosurgery, University Hospital Zurich, Zurich, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLiterature is inconclusive regarding the association between antiplatelet agents use and outcome after aneurysmal subarachnoid hemorrhage.

aimsTo investigate the association between clinical outcome and prehemorrhage use in aneurysmal subarachnoid hemorrhage patients as well as the impact of thrombocyte transfusion on rebleed and clinical outcome.

methodsData were collected from prospective databases of two European tertiary reference centers for aneurysmal subarachnoid hemorrhage patients. Patients were divided into "antiplatelet-user" and "non-user" according to the use of acetylsalicylic acid prior to the hemorrhage. Primary outcome was poor clinical outcome at six months (Glasgow Outcome Scale score 1-3). Secondary outcomes were in-hospital mortality and impact of thrombocyte transfusion.

resultsOf the 1033 patients, 161 (15.6%) were antiplatelet users. The antiplatelet users were older with higher incidence of cardiovascular risk factors. Antiplatelet use was associated with poor outcome and in-hospital mortality. After correction for age, sex, World Federation of Neurosurgical Societies score, infarction and heart disorder, pre-hemorrhage acetylsalicylic acid use was only associated with poor clinical outcome at six months (adjusted OR 1.80, 95% CI 1.08-3.02). Thrombocyte transfusion was not associated with a reduction in rebleed or poor clinical outcome.

conclusionIn this multicenter study, the prehemorrhage acetylsalicylic acid use in aneurysmal subarachnoid hemorrhage patients was independently associated with poor clinical outcome at six months. Thrombocyte transfusion was not associated with the rebleed rate or poor clinical outcome at six months.

Indexed as

StrokeSubarachnoid HemorrhageAspirinGlasgow Outcome ScaleHumansTreatment OutcomeAspirinacetylsalicylic acidAneurysmal subarachnoid hemorrhageantiplatelet agentmortalityoutcomerebleedthrombocyte transfusion

Identifiers

PMID34282988
PMCPMC9150139

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.